Abbott, EpiTherapeutics ink three-year cancer epigenetic deal
Start-up Danish biotech EpiTherapeutics APS has licensed Abbott Laboratories Inc. rights to small-molecule inhibitors against certain epigenetic targets for cancer.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.